OOIR: Observatory of International Research

Papers

(The H4-Index of Current Atherosclerosis Reports is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients	72
APOA1: a Protein with Multiple Therapeutic Functions	70
Social Determinants of Health and Cardiovascular Disease: Current State and Future Directions Towards Healthcare Equity	63
Food Insecurity and Cardiovascular Disease Risk	62
COVID and Cardiovascular Disease: What We Know in 2021	62
Periodontal Inflammation and the Risk of Cardiovascular Disease	57
CD36 in Atherosclerosis: Pathophysiological Mechanisms and Therapeutic Implications	56
Trimethylamine N-Oxide (TMAO), Diet and Cardiovascular Disease	54
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis	54
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?	51
High-Density Lipoproteins and Serum Amyloid A (SAA)	49
Time-Restricted Eating to Improve Cardiovascular Health	43
A Review of the Relationship Between CTRP Family and Coronary Artery Disease	42
Lipid Lowering Drugs: Present Status and Future Developments	40
The Role of the Gut Microbiota in Coronary Heart Disease	39
New Pharmacological Approaches to Target PCSK9	39
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions	38
The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review	38
Microparticles (Exosomes) and Atherosclerosis	37
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets	36
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	34
Birth Weight and Risk of Cardiovascular Disease Incidence in Adulthood: a Dose-Response Meta-analysis	33
The Long Non-coding Road to Atherosclerosis	33
Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care	32
Statins and Inflammation	32

The Association Between Periodontitis and Cardiovascular Disease: an Update	32
Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia	31
Clinical Pharmacology of Statins: an Update	30
Phytosterols and Cardiovascular Disease	30
Exosomes: Multifaceted Messengers in Atherosclerosis	29
Targeting Inflammation to Reduce Residual Cardiovascular Risk	29
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis	29